2 November 2019
Prioritis has launched its PrismHEOR platforms reinforcing its unique offer of daily, intelligent and reliable published and upcoming data regarding pharmaceutical HTA and reimbursement decisions.......
Prioritis has extended its offering to include an overview of different decision-analytic assessments across multiple HTA markets.
With its Prismaccess and PrismHEOR platforms, Prioritis delivers daily, intelligent and reliable published and upcoming data regarding pharmaceutical HTA and reimbursement decisions.
Prioritis is a global provider in market access solutions for pharmaceutical, biotechnology and medical devices. Prioritis undertakes support for pricing and reimbursement processes for new innovative drugs, extension of indications and reassessment of therapeutic areas.
Prismaccess platform contains a comprehensive, detailed record of HTA authorities’ decisions extracted into easy to navigate summaries. It provides an integrated service to support decision making at all stage of the product’s life with detailed information on recommendations, clinical and economic limitations.